To date, treatments with the objective to improve the quantity and quality of CD4+ T cells in COVID-19 have focused on addressing hyperactivation, anergy, or modulating specific cytokines, such as IL-1 and IL6 [43,71]. The gene discussed is CD4; the disease is COVID-19.